NS-2359

Source: Wikipedia, the free encyclopedia.
NS-2359
Clinical data
ATC code
  • none
Identifiers
  • (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-azabicyclo[3.2.1]octane
JSmol)
  • Clc1ccc(cc1Cl)C(C2COC)CC3NC2CC3
  (verify)

NS-2359 (GSK-372475) is a

phase I clinical trial exploring the effect of NS-2359 on cocaine-dependent individuals was completed in 2002.[5]

See also

References

  1. ^ a b "NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression". NeuroSearch.
  2. S2CID 9365152
    .
  3. .
  4. ^ Clinical trial number NCT00467428 for "Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder" at ClinicalTrials.gov
  5. ^ Clinical trial number NCT00032916 for "Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers" at ClinicalTrials.gov